1. Home
  2. SYNA vs NAMS Comparison

SYNA vs NAMS Comparison

Compare SYNA & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYNA
  • NAMS
  • Stock Information
  • Founded
  • SYNA 1986
  • NAMS 2019
  • Country
  • SYNA United States
  • NAMS Netherlands
  • Employees
  • SYNA N/A
  • NAMS N/A
  • Industry
  • SYNA Computer peripheral equipment
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SYNA Technology
  • NAMS Health Care
  • Exchange
  • SYNA Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • SYNA 2.2B
  • NAMS 2.5B
  • IPO Year
  • SYNA 2002
  • NAMS N/A
  • Fundamental
  • Price
  • SYNA $68.90
  • NAMS $19.16
  • Analyst Decision
  • SYNA Buy
  • NAMS Strong Buy
  • Analyst Count
  • SYNA 8
  • NAMS 8
  • Target Price
  • SYNA $94.29
  • NAMS $42.88
  • AVG Volume (30 Days)
  • SYNA 371.6K
  • NAMS 1.0M
  • Earning Date
  • SYNA 08-07-2025
  • NAMS 08-06-2025
  • Dividend Yield
  • SYNA N/A
  • NAMS N/A
  • EPS Growth
  • SYNA N/A
  • NAMS N/A
  • EPS
  • SYNA 4.13
  • NAMS N/A
  • Revenue
  • SYNA $1,038,900,000.00
  • NAMS $47,140,000.00
  • Revenue This Year
  • SYNA $13.82
  • NAMS N/A
  • Revenue Next Year
  • SYNA $8.97
  • NAMS N/A
  • P/E Ratio
  • SYNA $16.53
  • NAMS N/A
  • Revenue Growth
  • SYNA 10.60
  • NAMS 586.97
  • 52 Week Low
  • SYNA $41.80
  • NAMS $14.06
  • 52 Week High
  • SYNA $98.00
  • NAMS $27.29
  • Technical
  • Relative Strength Index (RSI)
  • SYNA 65.64
  • NAMS 52.90
  • Support Level
  • SYNA $64.27
  • NAMS $17.97
  • Resistance Level
  • SYNA $66.70
  • NAMS $19.13
  • Average True Range (ATR)
  • SYNA 2.00
  • NAMS 1.04
  • MACD
  • SYNA 0.24
  • NAMS -0.03
  • Stochastic Oscillator
  • SYNA 94.70
  • NAMS 35.63

About SYNA Synaptics Incorporated $0.001 Par Value

Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. Geographically, it derives a majority of revenue from China. The company operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: